

DAFTAR PUSTAKA

- American Cancer Society, 2009, *Cancer Facts and Figures*, Atlanta ,07-14.
- Andrijono, 2006, *Onkologi Genikologi*, Edisi I, FK UI, 45-50.
- Aurilio, Gaetano, MD, PhD et al., 2012, *Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report*, European Institute of Oncology, Medical Oncology, Milan, Italy, 4-5.
- Begg AC., 1997, *Cell Proliferation in tumors in Basic clinical radiobiology ed 2nd*, London, 14-5.
- Brunton LC, Lazo JS, Parker KL., 2006. *Goodman and Gilman's The pharmacological basis of therapeutics. Eleventh edition*, USA: Mc Graw Hill, 1335-1339.
- Cannon, Michael MD, and reviewed by the American College of Rheumatology Communications and Marketing Committee., 2013,3-7.
- Corwin, Elizabeth J., 2010, *Buku Saku Patofisiologi*, 750-752.
- Cox C., 2004, *Inhibition of growth of the squamous cell carcinoma by tetrathiomolybdate induced copper suppression on murine model*. Circulation research, 95-415.
- Departemen Kesehatan Republik Indonesia & Direktorat Jenderal Pengawasan Obat dan Makanan ,2000, *Parameter Standar Umum Ekstrak Tumbuhan Indonesia*. Jakarta : Departemen Kesehatan RI, 7-38.
- Fenton, Robert G, Longo, Dan L., 2008, *Cancer Cell Biology and Angiogenesis dalam Fauci*, Anthony S, Kasper Dennis L., Longo, Dan L, Braunwald, Eugene, Houser, Stephen L, Jameson J. Larry, Localzo, Joseph, Harrison's Principles Of Internals Medicine, volume I Edisi 17, 498-513.
- Habana A, Dokras A, Giraldo JL, Jones EE. 2012. Cornual heterotopic pregnancy: contemporary management options. *Am J Obstet Gynecol* 2000; 182: 1264-70. Comment in *Am J Obstet Gynecol* 2001; 185: 522.
- Harun N. & Syari, W., 2002, *Aktivitas antioksidan ekstrak daun dewa dalam menghambat sifat hepatotoksik halotan dengandosis sub anastesi pada mencit*. *Jurnal Sains dan Teknologi Farmasi* ,7(2): 63-70.
- Jemal A, Siegel R, Ward E., 2008,. *Cancer Statistic 2008*. *CA Cancer J Clin.*, 58, 71-96.

- Katzung, Bertram G., 2010, *Farmakologi Dasar & Klinik* Ed.10, EGC, Jakarta,564-567
- Merina ,2014 , *Aktifitas Imunomodulator Ekstrak Air dan Etanol Sarang Semut (Mysmecodia pedens Merr & Perry) pada Mencit Swiss Webster.t Swiss Webster.*
- Mudjahid ,2011, *Pengaruh pemberian sarang semut terhadap ekspresi p21 dan ekspresi ki67 pada galur sel karsinoma mammae T47D*,38.
- Nafrialdi, Gan S, Tirza D, Handoko T.,2003, *Antikanker dan imunosupresan*. In: Setiabudi R, Suyatma FD, Purwastyastuti, editors. *Farmakologi dan terapi*. Jakarta: Gaya Baru, 686-713.
- Price, Sylvia A., 2010 , *Patofisiologi Edisi 6 Volume 2*, 1303-1307.
- Robbins , 2006, *Buku Ajar Patologi*, 793-796.
- Sarjadi, 2007,*Karsinoma epidermoid serviks uteri (Beberapa aspek epidemiologi serta peran histopatologi dan petanda tumor dalam penentuan prognosis)*. Desertasi doctor Semarang: Universitas Diponegoro;.p. 8- 12).
- See D., 2002, *Transfer Factor Study with 20 cancer patients*. The journal of immunology,64-70.
- Sloane, E., 2004, *Anatomi Dan Fisiologi*. EGC: Jakarta, 67-70.
- Snell, R.S., 2006, *Anatomi Klinis Untuk Mahasiswa Kedokteran. Edisi Keenam*. EGC. Jakarta. 124-125.
- Subroto, M.A. & Saputro, H., 2006., *Gempur penyakit dengan sarang semut.Cetakan ertama, Penebar Swadaya Trubusno* 438 edisi XXXVII (Mei 2006). 45-46
- Sukardja IDG., 2000, *Onkologi Klinik. 2nded*, Surabaya: Airlangga University Press, 45-50.
- Sumarno, 2010, *Pengaruh Ekstrak Sarang Semut (Myrmecodia pendens) terhadap Aktifitas Proliferasi Sel dan Indeks Apoptosis Kanker Payudara Mencit C₃H*. 73.
- Suwiyoga, 2006 ,*Onkologi Ginekologi*, Edisi pertama, FK UI, Jakarta, 67-69.
- Tazulakhova EB, Parshia OV, Guseva TS, Ershov Fl., 2001, *Russian experience in screening, analysis dan clinical application of novel interferon inducers*. J Interferon Cytol : ine Res ;21(2):65-67.

- Tjindarbumi ,2004, *Penanganan Kanker Payudara Masa Kini dengan Berbagai Issue di Indonesia*. 1-14.
- Utami, Prapti, Mardiana, Lina, 2013, *Umbi Ajaib Tumpas Penyakit*, 35-45.
- Utami, Sri Anindya, 2008, *Efek Cyclophosphamid – Transfer factor terhadap proliferasi Sel (AgNOR) dan Volume Tumor Adenocarcinoma Mammarum Mencit*, 80- 85.
- Vlaming ML, 2011, *Impact of abcc2 (multidrug resistance-associated protein (MRP) 2), abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate*, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4-5.
- Wardlaw G. M., Jeffrey S. H., 2007, *Perspectives in Nutrition: the Vitamins and Minerals*. 7th ed, New York: Mc Graw Hill, pp: 318-320.
- Winarsi H. 2007. *Antioksidan Alami & Radikal Bebas*, Yogyakarta: Kanisius, pp: 82-77, 105-9, 147-55.
- Wunderlich JR., Restifo NP. 2005. *Essential of immunology*. In: Vincent TD, Samuel N, Steven AR. Editors. *Principle & Practice of oncology*. 5 ed. Philadelphia, Lippincott and Raven; p. 47- 75.
- Woodward WA, Strom EA, Tucker SL, et al.: Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. *J. Clin Oncol* 21 (17), 2-3.